Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3774136 | 0.87 | EGLN1 (0.52) | CYP2C9NR4A2NPC1RAB9AADORA2A | |
| SCHEMBL1733887 | 0.87 | ADORA2A (0.50) | CYP2C9NR4A2NPC1RAB9AADORA2A | |
| SCHEMBL3780900 | 0.87 | ADORA2A (0.50) | CYP2C9NR4A2NPC1RAB9AADORA2A | |
| SCHEMBL1734366 | 0.86 | ADORA2A (0.49) | CYP2C9NR4A2NPC1RAB9AADORA2A | |
| SCHEMBL3772491 | 0.85 | ADORA2A (0.51) | CYP2C9NR4A2RAB9AADORA2AEGLN1 | |
| SCHEMBL3771226 | 0.84 | ADORA2A (0.50) | CYP2C9NR4A2NPC1RAB9AADORA2A | |
| SCHEMBL1733561 | 0.84 | NR4A2 (0.58) | CYP2C9NR4A2NPC1RAB9AADORA2A | |
| SCHEMBL3779466 | 0.84 | CYP2C9 (0.61) | CYP2C9NR4A2NPC1RAB9AEGLN1 | |
| SCHEMBL3366348 | 0.84 | CYP2C9 (0.73) | CYP2C9NR4A2NPC1RAB9AEGLN1 | |
| SCHEMBL1733176 | 0.84 | ADORA2A (0.63) | CYP2C9NR4A2ADORA2AEGLN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225240-B1 | Derivatives of 6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2014-01-22 | — | — | EP | claimed |
| US-8314109-B2 | 6-heterocyclic-imidazo[1,2-α]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2012-11-20 | — | — | US | claimed |
| US-20100317675-A1 | 6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | claimed |
| US-8691990-B2 | 6-heterocyclic imidazo[1,2-α]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2014-04-08 | — | — | US | disclosed |
| EP-2225240-B1 | Derivatives of 6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2014-01-22 | — | — | EP | disclosed |
| US-20130041152-A1 | 6-HETEROCYCLIC IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | PEYRONEL JEAN-FRANCOIS (FR) | 2013-02-14 | — | — | US | disclosed |
| US-8314109-B2 | 6-heterocyclic-imidazo[1,2-α]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| US-20100317675-A1 | 6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130041152-A1 | 6-HETEROCYCLIC IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | XDH, REN, IDH2 | CYP2C9 209/4885NR4A2 2105/4885NPC1 2354/4885 |
| US-20100317675-A1 | 6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | REN, IDH2, GLS | CYP2C9 231/4885NR4A2 1987/4885NPC1 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.